tirzepatide studies 2025 Impact of 1-Year Use on Glycemic and Metabolic Profile in Overweight to Obese People with Type 1 Diabetes: A Systematic Review and Meta-Analysis Rising use of GLP-1 medications

A study of over 18,000 participants found that tirzepatide led to greater weight loss and improved blood sugar levels compared to semaglutide

People Who Stopped Taking Zepbound Were Still 22 Pounds Lighter on Average After 1 Year The purpose of this study was to find out if the impressive initial weight loss after the first eight months would continue beyond the period of active treatment

However, any spreading, painful, or breathing-related symptoms should prompt urgent care

Tirzepatide's extrapancreatic actions also contribute importantly to its cardiometabolic profile

And critically, does the quantity in the vial actually match what the label says

Yes this is a common and medically straightforward transition under provider supervision